Cosmetic Physician Partners Returns $35 Million to Employee Owners
DALLAS, July 22, 2026 Cosmetic Physician Partners (CPP) has announced a $35 million capital distribution to its practitioner-shareholders, marking...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DALLAS, July 22, 2026 Cosmetic Physician Partners (CPP) has announced a $35 million capital distribution to its practitioner-shareholders, marking...
Conshohocken, Pennsylvania, USA | July 20, 2026 AdaptHealth Corp. has entered into a definitive agreement to sell its Diabetes...
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
NEW YORK, July 7, 2026 Regal Healthcare Capital Partners has successfully completed the final close of Fund IV, securing...
